Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis
- 12 April 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (6), 1408-1414
- https://doi.org/10.1111/liv.14466
Abstract
Introduction In primary biliary cholangitis (PBC) macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in PBC patients. Methods We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (1) death from a liver‐related cause; or (2) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long‐term prognosis. Results Two‐hundred‐two PBC patients were included. Median age was 62 years (interquartile range (IQR), 53‐71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48‐5.35) and median sMR was 0.35 mg/L (IQR 0.28‐0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two‐hundred‐one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long‐term risk of liver related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR=1.14, 95% CI 1.00‐1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK‐PBC risk score. Conclusion The macrophage activation markers sCD163 and sMR represent a non‐invasive measure of PBC disease severity that provides useful long‐term prognostic information.Funding Information
- Italian Ministry of Education, University and Research (SIR RBSI14LOVD)
- Italian Ministry of Health (PE-2016-754 02363915, GR-2018-12367794)
This publication has 32 references indexed in Scilit:
- Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markersAutoimmunity Reviews, 2018
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological MechanismsThe Journal of Medical Investigation, 2017
- Toward precision medicine in primary biliary cholangitisDigestive and Liver Disease, 2016
- Primary biliary cirrhosisThe Lancet, 2015
- The Natural History of Primary Biliary CirrhosisSeminars in Liver Disease, 2014
- Autoimmune liver disease, autoimmunity and liver transplantationJournal of Hepatology, 2014
- The Immunobiology and Pathophysiology of Primary Biliary CirrhosisAnnual review of pathology, 2013
- Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosisJournal of Hepatology, 2010
- In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosisClinical Immunology and Immunopathology, 1986